Bristol-Myers Squibb Company
LAG-3 Combination Therapy for the Treatment of Cancer

Abstract:

The invention provides a medicament for use in treating a tumor in a human gastric or gastro-esophageal junction cancer patient, wherein the medicament is a LAG-3 antagonist, in particular an anti-LAG-3 antibody or a soluble LAG-3, alone or in combination with a PD-1 pathway inhibitor, in particular an anti-PD-1 antibody, and optionally one or more chemotherapeutic agents.